Drug delivery specialist CDMO Kindeva has announced the appointment of Daniel Couto as Executive VP, Inhalation & Specialty Drug Delivery. Couto was most recently COO at Vedanta Biosciences. His prior experience includes executive positions at Vedanta, ContraFect, Merck Sharp & Dohme Biologics, and Avecia Biologics.
The announcement cites the LGWP propellant transition, stating that Couto will “oversee Kindeva’s Inhalation & Specialty business as the company continues to invest in its development and manufacturing capabilities to support these changing requirements.” Kindeva has added several LGWP propellant MDI manufacturing lines to its Loughborough, UK facility as part of that investment. The company provides services for a full range of OINDPs, including DPIs, SMIs, and nasal delivery in addition to MDIs.
Kindeva CEO David Stevens commented, “Daniel is joining Kindeva at an important point in the growth and development of our Inhalation & Specialty business. We have a strong heritage in drug delivery, differentiated technologies and long-standing customer relationships, with a significant opportunity to build on those foundations. Daniel brings a rare combination of experience. He understands firsthand the challenges product innovators face in taking complex medicines from development through scale-up and commercialization, while also bringing deep experience in GMP manufacturing, operational leadership and building high-performing organizations.”
Couto said, “Kindeva has an exceptional heritage in drug delivery and a combination of scientific, engineering and manufacturing capabilities that can make a real difference for pharmaceutical and biotechnology companies developing complex products. These attributes represent a real competitive advantage for the industry, and I am excited to join the company at a time when both the inhalation market and the broader drug delivery landscape are evolving rapidly. I look forward to working with the Kindeva team and our customers to build on these capabilities, strengthen execution and bring more innovative medicines to patients.”
Read the Kindeva press release
